Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX002 in Moderately to Severely Active Ulcerative Colitis
NCT05156125Phase 2Terminated
- Sponsor
- Oppilan Pharma
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of tamuzimod in ulcerative colitis (UC) (3 arms), sponsored by Oppilan Pharma. Primary endpoint: Clinical Remission at 13 weeks. Started Nov 2021; status: terminated.
02
Drugs
tamuzimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05156125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156125.